148 related articles for article (PubMed ID: 21915031)
1. Tissue microarray analysis of ezrin, KBA.62, CD166, nestin, and p-Akt in melanoma versus banal and atypical nevi, and nonmelanocytic lesions.
Shanesmith RP; Smart C; Cassarino DS
Am J Dermatopathol; 2011 Oct; 33(7):663-8. PubMed ID: 21915031
[TBL] [Abstract][Full Text] [Related]
2. Potentially useful markers for desmoplastic melanoma: an analysis of KBA.62, p-AKT, and ezrin.
Bernaba BN; Vogiatzis PI; Binder SW; Cassarino DS
Am J Dermatopathol; 2011 Jun; 33(4):333-7; quiz 338-40. PubMed ID: 21610456
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of stem cell markers in malignant melanoma.
Klein WM; Wu BP; Zhao S; Wu H; Klein-Szanto AJ; Tahan SR
Mod Pathol; 2007 Jan; 20(1):102-7. PubMed ID: 17143262
[TBL] [Abstract][Full Text] [Related]
4. Nestin expression in cutaneous melanomas and melanocytic nevi.
Brychtova S; Fiuraskova M; Hlobilková A; Brychta T; Hirnak J
J Cutan Pathol; 2007 May; 34(5):370-5. PubMed ID: 17448190
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic utility of neural stem and progenitor cell markers nestin and SOX2 in distinguishing nodal melanocytic nevi from metastatic melanomas.
Chen PL; Chen WS; Li J; Lind AC; Lu D
Mod Pathol; 2013 Jan; 26(1):44-53. PubMed ID: 22899289
[TBL] [Abstract][Full Text] [Related]
6. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
[TBL] [Abstract][Full Text] [Related]
7. Expression of the ets-1 proto-oncogene in melanocytic lesions.
Keehn CA; Smoller BR; Morgan MB
Mod Pathol; 2003 Aug; 16(8):772-7. PubMed ID: 12920221
[TBL] [Abstract][Full Text] [Related]
8. Nestin and SOX9 and SOX10 transcription factors are coexpressed in melanoma.
Bakos RM; Maier T; Besch R; Mestel DS; Ruzicka T; Sturm RA; Berking C
Exp Dermatol; 2010 Aug; 19(8):e89-94. PubMed ID: 19845757
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness.
Bayer-Garner IB; Hough AJ; Smoller BR
Mod Pathol; 1999 Aug; 12(8):770-4. PubMed ID: 10463478
[TBL] [Abstract][Full Text] [Related]
10. p16ink4a expression in benign and malignant melanocytic conjunctival lesions.
Zoroquiain P; Fernandes BF; González S; Novais GN; Schalper KA; Burnier MN
Int J Surg Pathol; 2012 Jun; 20(3):240-5. PubMed ID: 22287653
[TBL] [Abstract][Full Text] [Related]
11. Cell adhesion and communication proteins are differentially expressed in melanoma progression model.
Rezze GG; Fregnani JH; Duprat J; Landman G
Hum Pathol; 2011 Mar; 42(3):409-18. PubMed ID: 21193224
[TBL] [Abstract][Full Text] [Related]
12. KBA.62: a useful marker for primary and metastatic melanomas.
Pagès C; Rochaix P; al Saati T; Valmary-Degano S; Boulinguez S; Launay F; Carle P; Lauwers F; Payoux P; Le Guellec S; Brousset P; Lamant L
Hum Pathol; 2008 Aug; 39(8):1136-42. PubMed ID: 18495211
[TBL] [Abstract][Full Text] [Related]
13. Wilms tumor 1 expression present in most melanomas but nearly absent in nevi.
Perry BN; Cohen C; Govindarajan B; Cotsonis G; Arbiser JL
Arch Dermatol; 2006 Aug; 142(8):1031-4. PubMed ID: 16924053
[TBL] [Abstract][Full Text] [Related]
14. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
Nazarian RM; Prieto VG; Elder DE; Duncan LM
J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
[TBL] [Abstract][Full Text] [Related]
15. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
[TBL] [Abstract][Full Text] [Related]
16. Expression of the neuroectodermal intermediate filament nestin in human melanomas.
Flørenes VA; Holm R; Myklebost O; Lendahl U; Fodstad O
Cancer Res; 1994 Jan; 54(2):354-6. PubMed ID: 8275467
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of COX-2 protein expression in melanocytic nevi in children].
Kubus M; Andrzejewska E; Nejc D; Kobos J; Taran K
Pol Merkur Lekarski; 2013 Aug; 35(206):82-4. PubMed ID: 24052986
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical double stains against Ki67/MART1 and HMB45/MITF: promising diagnostic tools in melanocytic lesions.
Nielsen PS; Riber-Hansen R; Steiniche T
Am J Dermatopathol; 2011 Jun; 33(4):361-70. PubMed ID: 21610457
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases.
Dai DL; Martinka M; Li G
J Clin Oncol; 2005 Mar; 23(7):1473-82. PubMed ID: 15735123
[TBL] [Abstract][Full Text] [Related]
20. Clusterin expression in primary and metastatic melanoma.
Busam KJ; Kucukgol D; Eastlake-Wade S; Frosina D; Delgado R; Jungbluth AA
J Cutan Pathol; 2006 Sep; 33(9):619-23. PubMed ID: 16965336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
